ONL Therapeutics Email Formats

Biotechnology Research • Ann Arbor, Michigan, United States • 21-50 Employees

ONL Therapeutics Email Formats

ONL Therapeutics uses 3 email formats. The most common is {first initial}{last name} (e.g., jdoe@onltherapeutics.com), used 57.1% of the time.

Format	Example	Percentage
{first initial}{last name}	jdoe@onltherapeutics.com	57.1%
{first name}{last name}	johndoe@onltherapeutics.com	28.6%
{last name}{last name}	doedoe@onltherapeutics.com	14.3%

Key Contacts at ONL Therapeutics

David Esposito

President And Chief Executive Officer

Brian Schickedanz

Director Clinical Operations

Amanda Maciel

Director Of Finance

Michael Woolliscroft

Senior Director, Financial Planning And Analysis

Company overview

Headquarters	524 S Main St, Suite 110, Ann Arbor, Michigan 48104, US
Phone number	+17344128787
Website	onltherapeutics.com
NAICS	541714
SIC	283
Keywords	Glaucoma, Retinal Detachment, Ophthalmic Drug Development, Geographic Atrophy
Founded	2011
Employees	21-50
Socials

About ONL Therapeutics

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to helping patients see the future. Our mission is to develop innovative therapeutics to protect and improve the vision of patients with a range of retinal disease and conditions. By advancing a breakthrough technology designed to prevent the death of key retinal cells caused by the activation of the natural Fas pathway, ONL is pioneering an entirely new approach to preserve sight. It is the first and only company focused on preventing Fas-mediated death of key retinal cells, which is a root cause of vision loss, a leading cause of blindness and an unaddressed medical need. ONL’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide Fas inhibitor designed to protect retinal cells from both death and inflammatory signaling pathways. ONL1204 Ophthalmic Solution is being developed for the treatment of retinal detachment, an acute condition for which the company has been granted orphan drug designation by the FDA. In addition, the company is currently developing ONL1204 in geographic atrophy associated with age-related macular degeneration, glaucoma, and other acute and chronic indications.

Employees by Management Level

Total employees: 21-50

Seniority

Employees

Entry

C-Suite

Manager

Employees by Department

ONL Therapeutics has 16 employees across 7 departments.

Departments

Number of employees

Funding Data

Explore ONL Therapeutics's funding history, including investment rounds, total capital raised, and key backers.

Funding Date	Round	Amount
2023-04-08	6	$15,000,000
2024-04-12	1	$10,000,000
2024-10-13	7	$65,000,000

Funding Insights

$90,000,000

Total funding amount

$65,000,000

Most recent funding amount

Number of funding rounds

ONL Therapeutics Tech Stack

Discover the technologies and tools that power ONL Therapeutics's digital infrastructure, from frameworks to analytics platforms.

Site Kit

Analytics

jQuery Migrate

JavaScript libraries

Twitter Emoji

Font scripts

MariaDB

Databases

jQuery

JavaScript libraries

PHP

Programming languages

HSTS

Security

WordPress

Blogs

Google Analytics

Analytics

Yoast SEO

SEO

Google Tag Manager

Tag managers

GoDaddy

Hosting

Frequently asked questions

ONL Therapeutics is located in Ann Arbor, Michigan, US.

You can reach ONL Therapeutics at +17344128787.

ONL Therapeutics was founded in 2011, making it 15 years old. The company has established itself as a significant player in its industry over this time.

ONL Therapeutics has approximately 21-50 employees. The company continues to grow its workforce to support its business operations and expansion.

ONL Therapeutics has raised a total of $90,000,000 across 3 funding rounds. This investment has helped the company grow and expand its operations.